This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.

Start Date01 Sep 2024

Sponsor / Collaborator

Royal Marsden NHS Foundation Trust

ACTRN12623001082695 / Not yet recruitingNot Applicable

Diagnostic Accuracy of 68Ga-PSMA PET/CT to identify residual Prostate Cancer Following Focal therapy with Irreversible Electroporation for localized Prostate Cancer: A Prospective Study

Start Date31 Oct 2023

Sponsor / Collaborator

St. Vincent's Private Hospitals Ltd.

NCT05562791 / RecruitingPhase 1IIT

Pilot Study of 68Gallium PSMA-PET/CT in Patients With Metastatic Urothelial Carcinoma or Melanoma

The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer. The study researchers want to learn if a 68Gallium PSMA PET/CT scan will work better, the same, or not as well as the PET/CT scans doctors usually use for imaging bladder cancer or skin cancer (FDG-PET/CT scan).

Start Date28 Sep 2022

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

100 Clinical Results associated with [68Ga]PSMA

100 Translational Medicine associated with [68Ga]PSMA

100 Patents (Medical) associated with [68Ga]PSMA

Literatures (Medical) associated with [68Ga]PSMA

01 Apr 2017·European Journal of Nuclear Medicine and Molecular ImagingQ1 · MEDICINE

Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC

Q1 · MEDICINE

Article

Author: Klutmann, Susanne ; Bannas, Peter ; Mester, Janos ; Kirchner, Uve ; Helberg, Annabelle ; Wester, Hans-Jürgen ; Tienken, Milena ; Kobayashi, Yuske ; Berliner, Christoph ; Frenzel, Thorsten ; Budäus, Lars ; Beyersdorff, Dirk

PURPOSETo determine the detection rate of PET/CT in biochemical relapse of prostate cancer using [⁶⁸Ga]PSMA I&T and to compare it with published detection rates of [⁶⁸Ga]PSMA HBED-CC.METHODSWe performed a retrospective analysis in 83 consecutive patients with documented biochemical relapse after prostatectomy. All patients underwent whole body [⁶⁸Ga]PSMA I&T PET/CT. PET/CT images were evaluated for presence of local recurrence, lymph node metastases, and distant metastases. Proportions of positive PET/CT results were calculated for six subgroups with increasing prostate specific antigen (PSA) levels (<0.5 ng/mL, 0.5 to <1.0 ng/mL, 1.0 to <2.0 ng/mL, 2.0 to <5.0 ng/mL, 5.0 to <10.0, ≥10.0 ng/mL). Detection rates of [⁶⁸Ga]PSMA I&T were statistically compared with published detection rates of [⁶⁸Ga]PSMA HBED-CC using exact Fisher's test.RESULTSMedian PSA was 0.81 (range: 0.01 - 128) ng/mL. In 58/83 patients (70 %) at least one [⁶⁸Ga]PSMA I&T positive lesion was detected. Local recurrent cancer was present in 18 patients (22 %), lymph node metastases in 29 patients (35 %), and distant metastases in 15 patients (18 %). The tumor detection rate was positively correlated with PSA levels, resulting in detection rates of 52 % (<0.5 ng/mL), 55 % (0.5 to <1.0 ng/mL), 70 % (1.0 to <2.0 ng/mL), 93 % (2.0 to <5.0 ng/mL), 100 % (5.0 to <10.0 ng/mL), and 100 % (≥10.0 ng/mL). There was no significant difference between the detection rate of [⁶⁸Ga]PSMA I&T and published detection rates of [⁶⁸Ga]PSMA HBED-CC (all p>0.05).CONCLUSIONS[⁶⁸Ga]PSMA I&T PET/CT has high detection rates of recurrent prostate cancer that are comparable to [⁶⁸Ga]PSMA HBED-CC.

100 Deals associated with [68Ga]PSMA

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 1	US	Memorial Sloan Kettering Cancer Center	28 Sep 2022
Prostatic Cancer	Discovery	IT	Ospedale San Raffaele Srl	03 Jun 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2024	Not Applicable	Prostatic Cancer	-	68Ga-PSMA (Healthy patients)	iutcbwzcps(rmdpihzmwt) = tffzhcioiq jkyaaovyqg (hmgskufgpk ) View more	-	09 Jun 2024
				68Ga-PSMA (Malignant prostate cancer patients)	iutcbwzcps(rmdpihzmwt) = ppcwgeskas jkyaaovyqg (hmgskufgpk ) View more
SNMMI2024	Not Applicable	-	-	68Ga-PSMA (68Ga-FAPI)	gvwofthotc(smjqzfpfov) = lucukocxmf ictlapjest (nwzgciypsd, 0.760)	-	09 Jun 2024
				68Ga-PSMA	gvwofthotc(smjqzfpfov) = qflheojrrf ictlapjest (nwzgciypsd, 0.709)
SNMMI2024	Not Applicable	Prostatic Cancer	-	68Ga-PSMA (68Ga-RM26 PET)	hulunzloto(tjqtesacyk) = paqmrzssrx zsisdppeqc (ejrnnnntnj ) View more	-	09 Jun 2024
				68Ga-PSMA (mpMRI)	hulunzloto(tjqtesacyk) = ehamgbfcrf zsisdppeqc (ejrnnnntnj ) View more
AUA2024	Not Applicable	-	-	68GA-PSMA	rhqjjvyqsu(bddbjskcyb) = tsxlucctno peadreisqm (tawszochxk )	-	01 May 2024
				68GA-PSMA	rhqjjvyqsu(bddbjskcyb) = pzgrkzkemb peadreisqm (tawszochxk )
NCT03396874 (CTgov)	Phase 2	Recurrent Prostate Carcinoma \| Metastatic Prostate Carcinoma \| Adenocarcinoma of prostate	1,435	68Ga-PSMA (68Ga-PSMA)	(oqlqxxkcmh) = pacfninlov qphgyblcwm (yfiugphuto, mouoxnbyjb - fxfxshgloq) View more	-	03 Nov 2023
				68Ga-PSMA-11 (Treatment Plans Up To 30 Days Post Scan)	osfqpdplbx(xftkmbgvga) = jfkioxrfnq gasmqluoel (dqxclktcgh, hidxfienlp - dgypbdjfcr) View more
SNMMI2023	Not Applicable	-	-	18F-rhPSMA -7.368Ga-PSMAA -7.3 (68Ga-PSMA PET-based nomogram)	pjdofmukgz(gkxkzviarw) = 8.8 months (95%CI 7.7-9.9) itkuhrmyfr (lxyufcdfqe ) View more	-	28 Aug 2023
				18F-rhPSMA -7.318F-rhPSMA-7.33 (18F-rhPSMA-7.3 PET)
SNMMI2023	Not Applicable	Advanced Prostate Carcinoma	-	177Lu-PSMA (99mTc-PSMA)	nteojxnyrx(rwqfoipayw) = badxtpmpcp aiieoaohoh (zaydksnzlg ) View more	-	28 Aug 2023
				177Lu-PSMA68Ga-PSMAA (68Ga-PSMA)	nteojxnyrx(rwqfoipayw) = vzbpdfykko aiieoaohoh (zaydksnzlg )
SNMMI2023	Not Applicable	Adenocarcinoma of prostate	-	68Ga-PSMAGA68PSMA (68Ga-PSMA PET/CT)	(caprmkemhk) = loekqqgaks badoskstac (mvebkuxdtz ) View more	-	28 Aug 2023
NCT04614363 (CTgov)	Phase 1/2	Prostatic Cancer	80	68Ga-PSMA (Localized High Risk Prostate Cancer)	tlymvgwopb(nzkeacyrfj) = ihmfleahxq vlzwrryaai (scrbfqjaox, iolvptzkit - jiocymzhfw) View more	-	29 Dec 2022
				68Ga-PSMA (Biochemical Recurrence)	tlymvgwopb(nzkeacyrfj) = zlyxvgqzga vlzwrryaai (scrbfqjaox, znoyzddosl - qjdduuhvhr) View more
ASTRO	Not Applicable	-	-	18F-fluciclovine	ibvxqqxjvc(rnmprqygji) = mwbwalsclj posbtkxklc (bzmugxmuxc ) View more	-	01 Nov 2022
				68Ga-PSMA18F-fluciclovine (68Ga-PSMA)	ibvxqqxjvc(rnmprqygji) = vgsmpugyrw posbtkxklc (bzmugxmuxc ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

[68Ga]PSMA

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation